PD173074

Name: PD173074
Brand: Selleck Chemicals
SKU: S1264
Rating: 5 (86 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1264

86 publications

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Selleck's PD173074 has been cited by 86 publications

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(2):2002922

PubMed: 33511016 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )
Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )

Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )

Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )
PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )

J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )

Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317712592

PubMed: 28718374 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )
Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1613-21

PubMed: 25535896 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

Targets

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1581	M4r3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2W1VGlEPTB;MD6wNVIzPSEQvF2=	NWHtPZpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KG-1	M1nKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYrn[2FVUUN3ME2wMlA2OTJ7IN88US=>	M{H2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MFM-223	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGHIXmNKSzVyPUCuNlE2PzZizszN	M{m5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EoL-1-cell	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYjJR\|UxRTBwM{K5PFQh\|ryP	NV72VJQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ECC10	NHO3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjBTWM2OD1yLkOzPFk5KM7:TR?=	MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYTXOGdDUUN3ME2wMlM1PzF3IN88US=>	Mn\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
AN3-CA	M4PzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGjHNGdKSzVyPUCuOFAyOzNizszN	NIjMcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HuO-3N1	NWK0O29mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEXtZZFKSzVyPUCuOVQ3PTNizszN	NGniToc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RT-112	NV\VWYplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFPVfHRKSzVyPUCuOVQ4ODFizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NEC8	NVPxOXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3JR\|UxRTBwNU[yPFkh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
D-263MG	M1W3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYPJR\|UxRTBwN{GxOVkh\|ryP	NXu4cohERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW962	NFHBVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmrRTWM2OD1yLke4PVg5KM7:TR?=	M3XPUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
BV-173	M1vnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MU\JR\|UxRTBwOES2NlMh\|ryP	NVfwWIZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MFE-280	NH\4bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrle3d[UUN3ME2wMlg2QDd{IN88US=>	NHXu[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HuH-7	NWfOdIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LiNmlEPTB;MT6yOFQ3PCEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
RS4-11	M1Tnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MULJR\|UxRTFwM{O4PFYh\|ryP	NX;zbVd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DMS-114	M3zYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVXJR\|UxRTFwM{[3N\|ch\|ryP	NWrLVJNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MSTO-211H	M{\OSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlXyTWM2OD1zLkS3N\|c5KM7:TR?=	M1zvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DU-145	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWX6emMxUUN3ME2xMlU5OjF5IN88US=>	NH[4Sno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A172	NFG5TnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEXBTXFKSzVyPUGuO\|A{PTVizszN	NULKeVI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SBC-1	NYjj[3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MonuTWM2OD1{LkC5OEDPxE1?	NEnYcGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
H9	M1zLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlHHTWM2OD1{LkG0N\|A3KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHjCO2ZKSzVyPUKuNVg{QTRizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H720	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoTQTWM2OD1{LkKxNlg{KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HCC2218	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHnXNFNKSzVyPUKuN\|c6OzlizszN	M3LuclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
G-401	M3zPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3S2cmlEPTB;Mj60O\|E5QSEQvF2=	NVnJTZZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MPP-89	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYLJR\|UxRTJwNEizOlQh\|ryP	M2fRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
697	NYHEb21kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{e4VmlEPTB;Mj62OVM{OSEQvF2=	M{fYPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KARPAS-45	NUnjdZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mk\TTWM2OD1{LkewO\|Q4KM7:TR?=	NXPzZoM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MG-63	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH[3PYtKSzVyPUKuPVQzPjJizszN	NHP0WIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	NWXEOFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXqwOFBDUUN3ME2zMlA{PDd{IN88US=>	NEnOTVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
G-402	M1npS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYfJR\|UxRTNwMUK3Nlch\|ryP	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NKM-1	NXrOcVNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHTENnNKSzVyPUOuNVM2PjRizszN	M{[xeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
RH-18	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmXITWM2OD1\|LkG5OVk5KM7:TR?=	NWLt[IQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1092	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFvoXHhKSzVyPUOuNVk3QSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
RPMI-8226	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PUSGlEPTB;Mz6yN\|Q1PyEQvF2=	MkjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
GAMG	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWjNN5ZIUUN3ME2zMlQ3PTd4IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HH	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2n3emlEPTB;Mz60O\|Y4PiEQvF2=	NEO5d\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RO82-W-1	M4fzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHT3eZNKSzVyPUOuOFk5PTVizszN	NETKUGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CCRF-CEM	NYnsdWY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmr6TWM2OD1\|LkWwOFg5KM7:TR?=	M3\JPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NBsusSR	NUmwWI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHvTWM2OD1\|Lk[zPVY6KM7:TR?=	MkfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CHL-1	NUXITWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGnidFNKSzVyPUOuOlU4QTlizszN	MmDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
LK-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYPmTHd3UUN3ME2zMlY4OTN\|IN88US=>	NEnkUmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Hs-578-T	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH\Ve5lKSzVyPUOuOlc5PzNizszN	NXnsOoQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CTB-1	NX2zd3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2XVR2lEPTB;Mz64NFA2OSEQvF2=	M4\yfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
ES5	M3y5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M37kcWlEPTB;Mz64N\|Y{PyEQvF2=	NVizeYlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A204	NFLQZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{SwcGlEPTB;Mz65NlA4PSEQvF2=	M4nTO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW780	M4\j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTNwOUKyOFUh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EW-3	NVTuZoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1LZPWlEPTB;Mz65PFkzOyEQvF2=	MnXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A704	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmjvTWM2OD12LkK4O\|I{KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-139	M2X4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlHVTWM2OD12LkOxOVM1KM7:TR?=	M3LF[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CAL-72	M3T0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVX0enlPUUN3ME20MlQyPzR4IN88US=>	M1;vW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-336MG	NVrYV5VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTueo5kUUN3ME20MlQ3QDF5IN88US=>	NHi5NHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LAMA-84	M3zVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFm1WHZKSzVyPUSuOVM{OSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GI-ME-N	MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoL4TWM2OD12LkW0PFEh\|ryP	NWWwZnB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KM-H2	NH3aWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFntNFJKSzVyPUSuOVUzOjJizszN	M3y4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H209	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX\WVYdkUUN3ME20MlU5Ojh\|IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
IGROV-1	NIK1UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M13qcGlEPTB;ND64O\|E3QCEQvF2=	NXy5eYdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
L-363	M1TNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWDJR\|UxRTRwOU[2OlUh\|ryP	NUXXeI1GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NXTWbplZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjhUIZKSzVyPUWuNlQxPiEQvF2=	NInPeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HuO9	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3PY[2lEPTB;NT6zPFg1OyEQvF2=	NWLpeI9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NOS-1	M4LTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVvF[YlSUUN3ME21MlczQTJ5IN88US=>	NFX0O3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1770	NXu5RmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVPvUXhCUUN3ME21Mlk2ODN{IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SF126	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITPSHVKSzVyPU[uNlE1ODZizszN	MlLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
ML-2	NYXFNpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MljSTWM2OD14LkK0PVc4KM7:TR?=	M1\6clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CHP-134	NWTSS3doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV3JR\|UxRTZwMkWxPFIh\|ryP	NVuwUY1sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1355	NYfJOFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{LWfGlEPTB;Nj60NVc{OyEQvF2=	MkfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
TE-12	M2\qdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mof6TWM2OD14LkeyOlcyKM7:TR?=	MlizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A4-Fuk	NV7jR4JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGD5fZpKSzVyPU[uO\|MyPDJizszN	NGe4[Vc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MV-4-11	M4fSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWTJR\|UxRTZwN{[2NlYh\|ryP	NGWxXGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SK-UT-1	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFrrT29KSzVyPU[uPVE4QDRizszN	NXHOTYtkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWHJR\|UxRTdwMEe3OlQh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ME-180	NUTSXlJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NULLVHhCUUN3ME23MlExPDB2IN88US=>	MmHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-28	NHj4SHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTdwM{e4NVkh\|ryP	MlzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HAL-01	NUDZemZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlXRTWM2OD15LkS4N\|QyKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ES8	M3zOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mlm1TWM2OD15Lk[5OlI3KM7:TR?=	NV7QWYw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DB	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnexTWM2OD16LkGxOVA1KM7:TR?=	Mom2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NH;JfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV3EN4Y4UUN3ME24MlQ5OTR7IN88US=>	M{LFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
COR-L88	NInpNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV\Vd3BtUUN3ME24MlUxQThzIN88US=>	MlPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWXJR\|UxRThwNUKyNVIh\|ryP	NFLtNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H520	NVHiflR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXfrfI5WUUN3ME24MlYzOTV5IN88US=>	M4K0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW954	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\2dmlEPTB;OD62PVc5PiEQvF2=	Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
TE-6	NYHrRZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVLJR\|UxRThwN{WxOFMh\|ryP	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
D-283MED	NWTJdlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mm\ETWM2OD17LkC2OVM1KM7:TR?=	M17abVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DBTRG-05MG	M1fpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTlwMEm2NFch\|ryP	M{\qeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H446	M2\Kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTlwMkm1NlYh\|ryP	NG\LS5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HOS	NVuwV5N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoPETWM2OD17LkO1NVM1KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ES4	M1r2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYryfpJRUUN3ME25MlUxPTl3IN88US=>	NWfsb3o3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EW-13	NYX3dVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPkTWM2OD17Lki5NFU2KM7:TR?=	NGqzcms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
IST-MES1	M3\r[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn7DTWM2OD17Lkm0OVM1KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CAS-1	M3Hle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHvsTVdKSzVyPUmuPVc3PTlizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EM-2	NGfuO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH;MdZFKSzVyPUGwMlE{QTNizszN	NYfxO4U3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW948	M3e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmrxTWM2OD1zMD6xPFgzKM7:TR?=	NFjySHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
OAW-42	NH;rSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFLy[5BKSzVyPUGwMlUzPjdizszN	Mn\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
BE-13	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2OxO2lEPTB;MUCuOlU4PiEQvF2=	M4nsUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KU812	Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEXpc2hKSzVyPUGwMlc{QTFizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-30	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV\JR\|UxRTFyLki5NFEh\|ryP	M4riSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A2780	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkPqTWM2OD1zMT6wN\|A5KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TGBC24TKB	NXr0NGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkK5TWM2OD1zMT6wO\|M4KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GOTO	NEm4U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYP2[5hkUUN3ME2xNU4zODh2IN88US=>	MmHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H526	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnfXTWM2OD1zMT6zPFM4KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
BHT-101	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHjOS4VKSzVyPUGxMlQ1PTZizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1155	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mk\qTWM2OD1zMT60PVQ4KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MCF7	NW\uT5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3\BfGlEPTB;MUGuOlE3PyEQvF2=	M4XzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MKN45	M33We2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTyTWM2OD1zMT63PVk{KM7:TR?=	NYrUdmdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MOLT-16	M{flc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHL5V\|NKSzVyPUGxMlk3QTJizszN	NF3vS4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
YH-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlHSTWM2OD1zMj6wN\|Q3KM7:TR?=	NVuxcIlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	NFq2RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkX1TWM2OD1zMj6zPFQ2KM7:TR?=	NVu3NXFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GR-ST	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4Ple2lEPTB;MUKuOVI6PSEQvF2=	NYDI[lc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CAKI-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGn2PFRKSzVyPUGyMlc6OSEQvF2=	M2ToeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LXF-289	NX3p[2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVi4epZQUUN3ME2xN{4xQDN3IN88US=>	NVfNbHFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnrmTWM2OD1zMz6yO\|A1KM7:TR?=	Ml;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
EW-16	NXLkfI1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjTfopKSzVyPUGzMlMyQDdizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H82	M3zvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnTaTWM2OD1zMz60NVk2KM7:TR?=	NGPOcYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MMAC-SF	M1:zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRTF\|LkS1OFch\|ryP	Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
COLO-684	NXS4[mdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfJR\|UxRTF\|LkWzNVgh\|ryP	MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	M1;NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUHHelREUUN3ME2xN{45OTB7IN88US=>	Ml3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NB69	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHHEW\|ZKSzVyPUGzMlk5PjhizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H2291	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvablFKSzVyPUG0MlQ1PTNizszN	MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MKN7	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHrBRo5KSzVyPUG0MlY3PzZizszN	M3jrS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HDLM-2	NFW1ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4PYT2lEPTB;MUWuNVI5PiEQvF2=	NV\lNI1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A253	M2Xse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFvXPJFKSzVyPUG1MlM5PjlizszN	NYCxTIxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-LU-1	NVPzZpNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFK5[GFKSzVyPUG1MlkxQTRizszN	NHi5bGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MEG-01	M3jrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTjTWM2OD1zNT65NVA4KM7:TR?=	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVLpd2dXUUN3ME2xOU46Ozd4IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
H4	NVXRdJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWLJR\|UxRTF4LkC4PEDPxE1?	NGrHTXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LU-65	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHPQdWRKSzVyPUG2MlM{QDRizszN	NYjJOXZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1048	M1fGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVfJR\|UxRTF4LkWxOlUh\|ryP	NGWyUno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LCLC-97TM1	M363R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH3VTnlKSzVyPUG2MlU5QDlizszN	NV22OWw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CAL-120	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3HhSmlEPTB;MU[uPVg4QSEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-134-A	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmW4TWM2OD1zNz6zN\|kyKM7:TR?=	M2S2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-MEL-1	M3TBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIfZTYNKSzVyPUG3MlcyOjdizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H69	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M172N2lEPTB;MUeuPVMxPyEQvF2=	Mo[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MC116	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\DWGlEPTB;MUeuPVc2KM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
UMC-11	NXrtTVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MY\JR\|UxRTF6LkG3PFgh\|ryP	NVvyc5NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCC1395	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGXhUpNKSzVyPUG4MlQ{ODFizszN	MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
no-10	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVHJR\|UxRTF6Lk[zPFgh\|ryP	NELqb4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NY	M3K1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4[3RmlEPTB;MUmuNFgxQSEQvF2=	NGHMcXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
OS-RC-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYLBcnNSUUN3ME2xPU4yOjV{IN88US=>	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
D-423MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NETxRm5KSzVyPUG5MlM6PTJizszN	M4\ZWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LC-2-ad	M3HBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHPXVHBKSzVyPUG5Mlc3OTJizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DU-4475	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUXJZmJFUUN3ME2xPU45QDV{IN88US=>	M{PPPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
YKG-1	NYfueFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYLhdIl3UUN3ME2xPU46PjJizszN	Moj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC1569	NVe0dHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTJyLkK2NlQh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TYK-nu	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUHCSYlOUUN3ME2yNE4zQDR5IN88US=>	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DEL	NIPuNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVLlPIt7UUN3ME2yNE46QDB6IN88US=>	MlK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MHH-ES-1	M{fNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkfuTWM2OD1{MT6zOVk4KM7:TR?=	NE\iSFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KARPAS-299	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGiwfpNKSzVyPUKxMlUzQSEQvF2=	M3P1[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CTV-1	NFG2VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVPpRWE3UUN3ME2yNU43OTd{IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H2452	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoTxTWM2OD1{Mj62Olc4KM7:TR?=	M1T6c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-566MG	M1riTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXTJR\|UxRTJ{Lke2NFEh\|ryP	M1XtcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EFO-27	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlzxTWM2OD1{Mz6wOlUyKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H596	M{HLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV;OOVJDUUN3ME2yN{45PTJ5IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KS-1	M1fGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4S3TmlEPTB;MkSuNlc2QSEQvF2=	NEWxRVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
8305C	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXzob4tLUUN3ME2yOE41ODR3IN88US=>	NVXxbmRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A427	M3q5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWX0bJR4UUN3ME2yOU4xOzJ\|IN88US=>	NEHmSJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
COLO-800	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWjZPZRqUUN3ME2yOU4yODZzIN88US=>	Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SJRH30	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnmwTWM2OD1{NT6zPVA5KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MEL-HO	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlz4TWM2OD1{NT60N\|E6KM7:TR?=	M2\HN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
FTC-133	M3KyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVPJR\|UxRTJ3LkixPFYh\|ryP	M4XGbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SF295	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHjSeohKSzVyPUK2MlI6PiEQvF2=	NWqxXmY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW1710	NWL6d5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1XCbGlEPTB;Mk[uOFEzOyEQvF2=	NV\kfFE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EFM-19	M37pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGHW[WRKSzVyPUK2MlgyPDVizszN	NEm4cnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NB10	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV7hZ2dlUUN3ME2yPE4zOjl5IN88US=>	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
TK10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXrYV2J4UUN3ME2yPE4zOzl7IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
D-502MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIjhVYxKSzVyPUK4MlQh\|ryP	NEjod4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EW-18	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3HsemlEPTB;MkiuOFM5PiEQvF2=	NWX5b3NSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	NGrTN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVTET49TUUN3ME2yPE46PDFizszN	NIP4[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Ca9-22	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnT6TWM2OD1{OT60OVU4KM7:TR?=	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KYSE-70	NX3SVVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2jLSWlEPTB;MkmuOVc5PiEQvF2=	NHW2PJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A101D	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NY\ZdHZbUUN3ME2yPU43PDd{IN88US=>	M4PMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
WM-115	M4jCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3v6O2lEPTB;MkmuO\|YxPyEQvF2=	M3frUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCC2157	NHPWSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIP3[m1KSzVyPUK5Mlg5ODdizszN	NESwfXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TE-9	NXHUUFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{XyfmlEPTB;MkmuPFg3PSEQvF2=	M2rWTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
K-562	NH\6WJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1LzSGlEPTB;M{CuNFk{OyEQvF2=	Ml\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SN12C	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1LOV2lEPTB;M{CuNVQzPiEQvF2=	NWPRPGlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ESS-1	M4XqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4Gzd2lEPTB;M{CuOFc2QSEQvF2=	Mn\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
K5	M4DxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWTJR\|UxRTNyLke2OEDPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
J82	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXnCSJdPUUN3ME2zNU4xQDl5IN88US=>	NYf3W3BvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HOP-92	NXns[5cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoDLTWM2OD1\|MT6xNVEyKM7:TR?=	M1P3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H2228	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHe4SVFKSzVyPUOxMlMzQTZizszN	NH6w[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
OCI-AML2	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1TKN2lEPTB;M{GuN\|YyKM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-SNU-5	NVXOZWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXnJR\|UxRTNzLkixN\|ch\|ryP	NVXnUZQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A3-KAW	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFfHcXZKSzVyPUOxMlkzPDNizszN	NVnzZndWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LCLC-103H	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVrOSmltUUN3ME2zNk4xOTdzIN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KY821	NYm2bWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\tT45KSzVyPUOyMlY5QDRizszN	NU\VWmRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
JVM-2	NG\Lb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3rBSmlEPTB;M{KuPVA4QSEQvF2=	NFHtRmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Mo-T	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3fWS2lEPTB;M{OuNVAxPSEQvF2=	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
IA-LM	NGPaOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1v5O2lEPTB;M{OuNlc2KM7:TR?=	M3jIWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
C8166	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4CycGlEPTB;M{OuN\|E6OiEQvF2=	NFrvTYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TCCSUP	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXTJR\|UxRTN\|LkSzNFch\|ryP	NWKxdIFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
JEG-3	NXvvdHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX\JR\|UxRTN\|LkS3Olgh\|ryP	NE\jVYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MS-1	NEjZZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;jNGlEPTB;M{OuOVU2OSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1304	M2\INWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV3INY9PUUN3ME2zN{42PzJ3IN88US=>	M3zIW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NU\ZS2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWrJR\|UxRTN2LkCzN\|Uh\|ryP	NFHsVnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MDA-MB-453	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWXFemZtUUN3ME2zOE43Ozl3IN88US=>	NHvO[ZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KYSE-520	NUS0N3BUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mom3TWM2OD1\|ND63NVgyKM7:TR?=	Mof1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SW900	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX35OWxwUUN3ME2zOE45OTF3IN88US=>	Mo\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC2998	NVjOTVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1\DN2lEPTB;M{WuNVUzQSEQvF2=	NVGxXVhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A2058	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoDtTWM2OD1\|NT62NFYyKM7:TR?=	M1L0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OVCAR-3	MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1fBNmlEPTB;M{[uNlA1PSEQvF2=	NXv1fFJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MOLT-4	NIrRclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1L0VGlEPTB;M{[uNlI6PCEQvF2=	NHXZdoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CAPAN-1	NVnxWFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWPJR\|UxRTN4LkS2PVkh\|ryP	Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SCC-9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4nJcWlEPTB;M{euOFAzPyEQvF2=	M{XRcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SF268	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlW3TWM2OD1\|OD6zOFM{KM7:TR?=	MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HGC-27	NFPZfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2\NSmlEPTB;M{iuN\|cyOSEQvF2=	NUPHTXFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DOHH-2	NVvTWoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTN6LkexOVgh\|ryP	MofFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KE-37	M4n1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX7nSHc3UUN3ME2zPE46QDJ6IN88US=>	NELi[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MOLT-13	NUTqUWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3;HTGlEPTB;M{muNlUxOiEQvF2=	NIjLdlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES1	NXX0OFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXrpSVVtUUN3ME2zPU4{QDVizszN	NX:3UI9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-OV-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVvJR\|UxRTN7Lkm2OFMh\|ryP	Mn;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SNU-449	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFrIO5hKSzVyPUSwMlA4PjRizszN	NIjOcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KYSE-510	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkXLTWM2OD12MD6xNlk2KM7:TR?=	M1vFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HL-60	NHr0ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mn\KTWM2OD12MD65O\|g{KM7:TR?=	M2OzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DJM-1	M2njPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEDLfGVKSzVyPUSwMlk4QTlizszN	NYPSeIp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
TGBC11TKB	M3vsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWTJR\|UxRTRzLkC5NlYh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
U-2-OS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn;STWM2OD12Mj6yOlQyKM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H2030	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1H0cGlEPTB;NEKuOFM3QCEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-135	NEfOPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHWZ45KSzVyPUSyMlU1PDdizszN	NUfqVZhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ZR-75-30	M17wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXnJR\|UxRTR\|LkC0PVMh\|ryP	NF;hc\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
GT3TKB	NIn3N\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3\yVWlEPTB;NEOuNlY4QSEQvF2=	NVvTWZNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RPMI-2650	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX;VNnRbUUN3ME20N{44QDF4IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SAS	NWDEbWdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;xSWlEPTB;NEOuPVU{PCEQvF2=	MkPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-231	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn75TWM2OD12Mz65OlA6KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
JVM-3	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmThTWM2OD12ND6wOVM{KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	M3j0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoH6TWM2OD12ND61OlM{KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SNB75	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\rTWM2OD12ND62NVA2KM7:TR?=	M4rRcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H441	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXHJR\|UxRTR2LkmzNlgh\|ryP	NVn5bFdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCT-116	NVP6VnlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIm0e3FKSzVyPUS0Mlk5PjhizszN	NUO5dFY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H226	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NED4d49KSzVyPUS1MlY{PjhizszN	MlfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CAL-33	NHTwT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml6xTWM2OD12NT65NlE4KM7:TR?=	NYTscVdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1437	NU\6cFhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml7STWM2OD12Nj6zNlEh\|ryP	M3vjNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCC1187	NUW4dmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mo\6TWM2OD12Nj60NlU2KM7:TR?=	M2S5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NUGC-3	NHzOZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1vhVWlEPTB;NE[uOVcxQSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
T98G	NVLoO3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGPud\|RKSzVyPUS3MlU1PyEQvF2=	M3\YdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OVCAR-8	NXPpSXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoLlTWM2OD12Nz62PFMh\|ryP	NGC5TlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LB2241-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4DXemlEPTB;NEeuO\|I4KM7:TR?=	M{HmbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H358	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkPYTWM2OD12OD6xNVUzKM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
PANC-08-13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUK1cFB6UUN3ME20PE4yQDV\|IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KP-N-YN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHy1RpZKSzVyPUS4MlIyODJizszN	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H1755	NES0[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWnJR\|UxRTR6LkK3NlYh\|ryP	M2LvbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-N87	NGLwTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXrJR\|UxRTR6LkK5PVEh\|ryP	M2npZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SUM52	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUe1JIRigXN?	M3TK[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRlfGVlIu[W2ybHnmbYVlKFOXTUWyJINmdGy\|IHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCxNlMh\|ryPLh?=	NUixOnFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlEyPTZpPkK4OVIyOTV4PD;hQi=>
RT112	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFXYRZc4OiCqcoO=	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkCxOUDPxE1w	NHrEO2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PVc1Oid-Mke1PVk4PDJ:L3G+
insect cells	MnnUSpVv[3Srb36gZZN{[Xl?		NG\HS5IyOCCvaX7z	NVzOPXY5UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBHT0[UMTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[S1\|MmDdRXRRKGGodHXyJFExKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDiZZNm\CC{YXTpc4FkfGm4ZTDmbYx1\XJiYnnu[Ilv\yCjc4PhfUwhUUN3MDC9JFAvODJzNTFOwG0v	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzNEO2Nkc,Ojd7MUSzOlI9N2F-
SW780	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M13lVFUh\GG7cx?=	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[JRmKzMYFueGyrZnnl[EBUXzd6MDDj[YxteyCjZoTldkA2KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yOESzJO69VS5?	MnvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkGxOVYoRjJ6NUKxNVU3RC:jPh?=
NIH/ 3T3	MlfISpVv[3Srb36gZZN{[Xl?		M4GxRVUhdWmwcx?=	NU\vdWZQUW6qaXLpeIlwdiCxZjDWSWdHWjJiKIXub45wf25ib4Lp[4lvMSCxdnXy[ZhxemW\|c3XkJIlvKG2xdYPlJG5KUC9iM2SzJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIZwdGyxd3XkJIJ6KHO2aX31cIF1cW:wIIfpeIghXkWJRjDmc5IhPSCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nzMEBKSzVyIE2gNE4yKM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN{NkOzPUc,Ojd\|Mk[zN\|k9N2F-
NCI-H520	NF;qSotCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXrDcHhWPyCmYYnz	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[JRmKxMYFueGyrZnnl[EBPS0lvSEWyNEBk\WyuczDh[pRmeiB5IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6yPFEh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{MUG1Okc,Ojh3MkGxOVY9N2F-
HUVEC	NHPGOGJHfW6ldHnvckBie3OjeR?=	MXmxNEBvVQ>?	Mn;uNVQhcHK\|	MX;Jcohq[mm2aX;uJI9nKE[JRmKtcYVlcWG2ZXSgZY5ocW:pZX7ld4l{KGmwIHj1cYFvKEiXVlXDJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOjcHnscIFzgSC2dXLlJJNxem:3dHnu[{BifCBzMDDuUUBi\nSncjCxOEBpenN?	NFLD[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS3OFM5Pyd-MU[0O\|Q{QDd:L3G+
HUVEC	NXTz[5F1TnWwY4Tpc44h[XO\|YYm=	NWfpcmJVOTByIH7N	MVqxOEBpenN?	MkTLTY5pcWKrdHnvckBw\iCIR1\SMY1m\GmjdHXkJIFv\2mxZ3Xu[ZNqeyCrbjDoeY1idiCKVW\FR{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClYYDpcIxienlidIXi[UB{eHKxdYTpcoch[XRiMUCwJI5OKGGodHXyJFE1KGi{cx?=	NH3EdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS3OFM5Pyd-MU[0O\|Q{QDd:L3G+
SJ-GBM2	MY\xTHRUKGG\|c3H5			M1jDbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NIi1WlNyUFSVIHHzd4F6			NWP1SGNVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NEDx[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MnnmdWhVWyCjc4PhfS=>			Mn;IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MmPmdWhVWyCjc4PhfS=>			NX\hXG55eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M1\xbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NIPFelJyUFSVIHHzd4F6			M3\LZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NFjxfnFyUFSVIHHzd4F6			NHi0UINyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NYnxN2FHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MUDxTHRUKGG\|c3H5			Mn3zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	M4rwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MnLvdWhVWyCjc4PhfS=>			NGrDPXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NIXRVGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M3HIN5FJXFNiYYPzZZk>			M1vsN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NHfZWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MlzVdWhVWyCjc4PhfS=>			M37MR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NHnZUG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast cells	M4C3R5FJXFNiYYPzZZk>			NWjGUI1VeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IHPvcpRzd2xiSHige4lt\CC2eYDlJIZq[nKxYnzhd5Qh[2WubIO=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NEHUVFByUFSVIHHzd4F6			MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

In vivo

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-³²P]ATP (5 μM ATP containing 0.4 μCi of [γ-³²P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [³²P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:^[4]	- Collapse Cell lines: KMS11 and KMS18 Concentrations: Dissolved in DMSO, final concentrations ~100 nM Incubation Time: 48 hours Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Swiss Webster mice with induced corneal angiogenesis Dosages: ~2 mg/kg/day Administration: Administered intraperitoneally (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD173074 SDF

Molecular Weight	523.67
Formula	C₂₈H₄₁N₇O₃
CAS No.	219580-11-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of PD173074(S1264) in vivo?
Answer:
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Pan FGFR Inhibitor

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
Most Potent FGFR Inhibitor

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Related FGFR Products

CH5183284 (Debio-1347) ^New

CH5183284 (Debio-1347, FF284) is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Infigratinib (BGJ398)

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
AZD4547

AZD4547 (ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074